Amarin Accused Of Pumping Up Stocks Before FDA Snub

Law360, Los Angeles (November 7, 2013, 4:29 PM EST) -- Amarin Corp. PLC artificially inflated its stock price before a U.S. Food and Drug Administration panel denied expanded use of its fish oil drug Vascepa among adults with high fat levels, according to a putative class action filed in New York federal court Tuesday.

The shareholder suit accuses executives at the biopharmaceutical company of breaking securities laws by misleading investors into believing the FDA would approve the drug when they knew the drug might not have any meaningful cardiovascular benefits.

The putative class consists of an...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Bove et al v. Amarin Corporation, PLC. et al


Case Number

1:13-cv-07882

Court

New York Southern

Nature of Suit

Securities/Commodities

Judge

Analisa Torres

Date Filed

November 5, 2013

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.